OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Definition of minimal disease activity in psoriasis
G. Carretero, J.M. Carrascosa, L. Puig, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 422-430
Closed Access | Times Cited: 19
G. Carretero, J.M. Carrascosa, L. Puig, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 422-430
Closed Access | Times Cited: 19
Showing 19 citing articles:
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2021) Vol. 113, Iss. 3, pp. 261-277
Open Access | Times Cited: 39
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2021) Vol. 113, Iss. 3, pp. 261-277
Open Access | Times Cited: 39
A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
L. Salgado‐Boquete, J.M. Carrascosa, Mar Llamas‐Velasco, et al.
Life (2021) Vol. 11, Iss. 7, pp. 627-627
Open Access | Times Cited: 32
L. Salgado‐Boquete, J.M. Carrascosa, Mar Llamas‐Velasco, et al.
Life (2021) Vol. 11, Iss. 7, pp. 627-627
Open Access | Times Cited: 32
Estudio del impacto de las restricciones en el acceso a fármacos biológicos en psoriasis sobre la actividad mínima de la enfermedad: subanálisis de los proyectos EQUIDAD y AME de la AEDV
M. Sánchez-Díaz, Ángeles Flórez, G. Carretero‐Hernández, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 9, pp. 906-911
Open Access | Times Cited: 2
M. Sánchez-Díaz, Ángeles Flórez, G. Carretero‐Hernández, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 9, pp. 906-911
Open Access | Times Cited: 2
Belgian recommendations for managing psoriasis in a changing treatment landscape
Reinhart Speeckaert, Arjen Nikkels, Jo Lambert, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 2
Reinhart Speeckaert, Arjen Nikkels, Jo Lambert, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 2
Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians
Irons Ee, Elfie Deprez, Alexander Egeberg, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 3, pp. 403-412
Open Access | Times Cited: 16
Irons Ee, Elfie Deprez, Alexander Egeberg, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 3, pp. 403-412
Open Access | Times Cited: 16
[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 3, pp. T261-T277
Open Access | Times Cited: 6
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 3, pp. T261-T277
Open Access | Times Cited: 6
Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the “minimal disease activity” parameter
Jorge Magdaleno‐Tapial, Sergio Santos‐Alarcón, Marta Carolina Serra‐Torres, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 6
Closed Access | Times Cited: 6
Jorge Magdaleno‐Tapial, Sergio Santos‐Alarcón, Marta Carolina Serra‐Torres, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 6
Closed Access | Times Cited: 6
Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study
Chang‐Yu Hsieh, Yu‐Hsian Tseng, Tsen‐Fang Tsai
Experimental Dermatology (2023) Vol. 32, Iss. 12, pp. 2138-2148
Open Access | Times Cited: 3
Chang‐Yu Hsieh, Yu‐Hsian Tseng, Tsen‐Fang Tsai
Experimental Dermatology (2023) Vol. 32, Iss. 12, pp. 2138-2148
Open Access | Times Cited: 3
Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation
Deepak Balak, Lourdes M. Pérez-Chada, Lisa N. Guo, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 12, pp. 2291-2300
Closed Access | Times Cited: 4
Deepak Balak, Lourdes M. Pérez-Chada, Lisa N. Guo, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 12, pp. 2291-2300
Closed Access | Times Cited: 4
Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America: A Case Series Review
Iván Chérrez-Ojeda, Karla Robles‐Velasco, Simon Francis Thomsen, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 661-672
Open Access | Times Cited: 2
Iván Chérrez-Ojeda, Karla Robles‐Velasco, Simon Francis Thomsen, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 661-672
Open Access | Times Cited: 2
Reply to “Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the “minimal disease activity” parameter”
Giulia Murgia, Carlo Alberto Maronese, Carlo Giovanni Carrera, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Open Access | Times Cited: 3
Giulia Murgia, Carlo Alberto Maronese, Carlo Giovanni Carrera, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Open Access | Times Cited: 3
52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience
Francisco Javier Melgosa Ramos, Almudena Mateu Puchades, J. Matáix-Díaz, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 7, pp. 722-726
Open Access
Francisco Javier Melgosa Ramos, Almudena Mateu Puchades, J. Matáix-Díaz, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 7, pp. 722-726
Open Access
52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience
Francisco Javier Melgosa Ramos, Almudena Mateu Puchades, J. Matáix-Díaz, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 7, pp. T722-T726
Open Access
Francisco Javier Melgosa Ramos, Almudena Mateu Puchades, J. Matáix-Díaz, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 7, pp. T722-T726
Open Access
Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional
G. Carretero Hernández, Mariano Ara Martín, Selena Alonso, et al.
Actas Dermo-Sifiliográficas (2024)
Open Access
G. Carretero Hernández, Mariano Ara Martín, Selena Alonso, et al.
Actas Dermo-Sifiliográficas (2024)
Open Access
Estudio del impacto de las restricciones en el acceso a fármacos biológicos en psoriasis sobre la actividad mínima de la enfermedad: subanálisis de los proyectos EQUIDAD y AME de la AEDV
M. Sánchez Díaz, Ángeles Flórez, G. Carretero‐Hernández, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 9, pp. T906-T911
Open Access
M. Sánchez Díaz, Ángeles Flórez, G. Carretero‐Hernández, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 9, pp. T906-T911
Open Access
Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional
G. Carretero Hernández, Mariano Ara Martín, Selena Alonso, et al.
Actas Dermo-Sifiliográficas (2024)
Open Access
G. Carretero Hernández, Mariano Ara Martín, Selena Alonso, et al.
Actas Dermo-Sifiliográficas (2024)
Open Access
Napkin psoriasis and the risk of later psoriasis development: A single‐centre retrospective study
Iria Neri, Miriam Leuzzi, Martina Mussi, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access
Iria Neri, Miriam Leuzzi, Martina Mussi, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access
Ixekizumab y psoriasis en la práctica clínica real, una alternativa en presencia de artritis y en localizaciones especiales
Francisco Javier Melgosa Ramos, Ana Isabel Zayas Gavilá, José María Sánchez Motilla, et al.
Piel (2022) Vol. 37, Iss. 10, pp. 584-589
Closed Access
Francisco Javier Melgosa Ramos, Ana Isabel Zayas Gavilá, José María Sánchez Motilla, et al.
Piel (2022) Vol. 37, Iss. 10, pp. 584-589
Closed Access
Reply to Murgia et al., about “Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice: A retrospective multicenter study using the “minimal disease activity” parameter”
Jorge Magdaleno‐Tapial
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Closed Access
Jorge Magdaleno‐Tapial
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Closed Access
